Epidemiology and clinical predictors of biphasic reactions in children with anaphylaxis

Waleed Alqurashi1, Ian Stiell2, Kevin Chan3

  • 1Department of Pediatrics and Emergency Medicine, University of Ottawa, Ottawa, Ontario, Canada; Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Insights

Biphasic reactions in children experiencing anaphylaxis occur in 14.7% of cases. Key predictors include age, delayed emergency department presentation, and initial reaction severity, informing prolonged monitoring needs.

Area of Science:

  • Pediatric Emergency Medicine
  • Allergy and Immunology
  • Clinical Epidemiology

Background:

  • Epidemiologic data on biphasic reactions in pediatric anaphylaxis are limited.
  • Biphasic reactions, a recurrence of symptoms after initial improvement, pose a significant clinical challenge.

Purpose of the Study:

  • To determine the incidence of biphasic reactions in children with anaphylaxis.
  • To identify clinical predictors associated with biphasic reactions in pediatric patients.

Main Methods:

  • Retrospective review of emergency department (ED) health records at two Canadian academic pediatric centers.
  • Inclusion criteria: ED visits meeting National Institute of Allergy and Infectious Diseases and Food Allergy and Anaphylaxis Network anaphylaxis criteria.
  • Analysis of biphasic reaction predictors using univariate and multiple logistic regression.

Main Results:

  • Of 484 eligible visits, 71 (14.7%) experienced biphasic reactions.
  • Independent predictors identified: age 6-9 years, delayed ED presentation (>90 min), wide pulse pressure, multiple epinephrine doses for initial reaction, and inhaled beta-agonist use.
  • Biphasic reactions often involved respiratory/cardiovascular symptoms and required epinephrine.

Conclusions:

  • Biphasic reactions in pediatric anaphylaxis are linked to initial reaction severity.
  • Identified clinical predictors can aid in selecting children for extended ED observation.
  • Findings support optimized resource allocation in pediatric emergency care for anaphylaxis.
Abstract

Related Concept Videos

Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
188
Allergic Reactions02:06

Allergic Reactions

Overview
33.9K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
786
Cross-reactivity00:42

Cross-reactivity

Overview
34.0K
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
225
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
346